CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026
Rhea-AI Summary
CorMedix (Nasdaq: CRMD) will report its fourth quarter and full year 2025 financial results for the period ended December 31, 2025, before the market opens on Thursday, March 5, 2026. The company will host a corporate update conference call at 8:30am Eastern Time.
Investors can join by domestic phone 1-844-676-2922, international phone 1-412-634-6840, or via webcast.
Positive
- None.
Negative
- None.
News Market Reaction – CRMD
In the Mar 2 session, CRMD gained 1.12%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 12 | Investor conferences | Positive | -0.9% | Planned participation in three March 2026 healthcare investor conferences. |
| Feb 02 | Share repurchase plan | Positive | +5.3% | Board authorized up to $75 million in stock repurchases through 2027. |
| Jan 29 | Analyst Day announcement | Positive | +3.5% | Planned in-person and virtual Analyst Day with portfolio and pipeline updates. |
| Jan 09 | Conference presentation | Positive | +1.6% | Corporate overview scheduled at the 44th Annual J.P. Morgan Healthcare Conference. |
| Jan 08 | Leadership changes | Positive | -32.8% | CEO contract extension and board role changes alongside comments on cashflow strength. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has mostly been strategic and investor-relations focused, with generally positive reactions except for a sharp selloff on leadership and board updates, indicating occasional divergence between seemingly positive headlines and price moves.
Over the last few months, CorMedix has highlighted investor outreach and corporate developments. It announced multiple March 2026 investor conferences, an Analyst Day on February 10, 2026, and participation in the 44th Annual J.P. Morgan Healthcare Conference. A Board‑authorized share repurchase program of up to $75 million through December 31, 2027 coincided with a positive price move. By contrast, leadership and board changes on January 8, 2026 were followed by a steep -32.77% reaction, showing the market can respond sharply to governance headlines.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BERKELEY HEIGHTS, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Thursday, March 5, 2026, and will host a corporate update conference call at 8:30am Eastern Time.
| Thursday, March 5th @ 8:30am ET | |
| Domestic: | 1-844-676-2922 |
| International: | 1-412-634-6840 |
| Webcast: | Webcast Link |
About CorMedix
CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. CorMedix is commercializing DefenCath® (taurolidine and heparin) for the prevention of catheter-related bloodstream infections in adult patients undergoing hemodialysis via a central venous catheter. Following its August 2025 acquisition of Melinta Therapeutics LLC, CorMedix is also commercializing a portfolio of anti-infective products, including MINOCIN® (minocycline) for Injection, REZZAYO® (rezafungin for injection), VABOMERE® (meropenem and vaborbactam), ORBACTIV™ (oritavancin), BAXDELA® (delafloxacin), and KIMYRSA® (oritavancin), as well as TOPROL-XL® (metoprolol succinate).
CorMedix has ongoing clinical studies for DefenCath in Total Parenteral Nutrition (TPN) and Pediatric Hemodialysis populations and also intends to develop DefenCath as a catheter lock solution for use in other patient populations. REZZAYO is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of IFD in adult patients undergoing allogeneic BMT. Topline results of the Phase III study for REZZAYO are expected in Q2 2026. For more information visit: www.cormedix.com or www.melinta.com.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
